We Help Companies Find New Sales Opportunities
Cambridge Antibody Technology
Cambridge Antibody Technology is to set up a new 92,000 sq ft research and manufacturing centre at Granta Park in Cambridge by 2008, as part of an expansion programme that will create 300 jobs.
Cambridge Antibody Technology is to sell an 11% equity stake to Genzyme of the US for £23m, as part of a collaboration between the two companies in the development of drugs for fibrotic diseases.
Cambridge Antibody Technology has offered to acquire Oxford Glycosciences for £110m, and the group's combined cash reserve of £260m will be used to license new drugs or acquire another biotechnology company.
Cambridge Antibody Technology is planning to increase research spending by 60%, raise headcount from 270 to 300 and consolidate its Cambridgeshire operations onto one site.
Cambridge Antibody Technology is to acquire Drug Royalty Corporation of Canada for £55m.
Cambridge Antibody Technology is forming an alliance with Immunex of the US to develop antibody-based treatments for auto-immune and inflammatory disorders.
Cambridge Antibody Technology is to relocate its Cambridgeshire headquarters from Melbourn to Granta Park in Great Abington over the next two years, which will involve the relocation of 180 jobs and the creation of 70 new jobs.
Cambridge Antibody Technology is forming an alliance with Human Genome Sciences of the US to develop new pharmaceutical products using CAT's technology.